BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37403111)

  • 21. Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease - a randomized, open-label, multicenter phase II trial.
    Bozorgmehr F; Christopoulos P; Chung I; Cvetkovic J; Feißt M; Krisam J; Schneider MA; Heußel CP; Kreuter M; Müller DW; Thomas M; Rieken S
    BMC Cancer; 2022 Sep; 22(1):1011. PubMed ID: 36153496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of thoracic radiotherapy combined with chemo-immunotherapy in patients with extensive-stage small cell lung cancer: a multicenter retrospective analysis.
    Cai Z; Gu X; Xie J; Cheng D; Chen J; Cheng J; Ye J; Lv T
    Transl Lung Cancer Res; 2023 Oct; 12(10):1987-2000. PubMed ID: 38025813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of durvalumab + chemotherapy
    Zou Y; Ren X; Zhang H; Wang Y; Wang H; Bai R; Zhang Z; Sun G; Xu L
    J Thorac Dis; 2023 Jun; 15(6):3339-3349. PubMed ID: 37426159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thoracic radiotherapy may improve the outcome of extensive stage small cell lung carcinoma patients treated with first-line immunotherapy plus chemotherapy.
    Wu JJ; Huang JW; Hsu KH; Huang YH; Chen KC; Tseng JS; Yang TY; Chang GC
    Anticancer Drugs; 2022 Nov; 33(10):e842-e849. PubMed ID: 36206101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer.
    Zhou F; Zhao W; Gong X; Ren S; Su C; Jiang T; Zhou C
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-line atezolizumab/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer.
    Li L; Yang D; Min Y; Liao A; Zhao J; Jiang L; Dong X; Deng W; Yu H; Yu R; Zhao J; Shi A
    BMC Cancer; 2023 Apr; 23(1):318. PubMed ID: 37024843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Receipt of thoracic radiation therapy and radiotherapy dose are correlated with outcomes in a retrospective study of three hundred and six patients with extensive stage small-cell lung cancer.
    Li-Ming X; Zhao LJ; Simone CB; Cheng C; Kang M; Wang X; Gong LL; Pang QS; Wang J; Yuan ZY; Wang P
    Radiother Oncol; 2017 Nov; 125(2):331-337. PubMed ID: 29079309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Impact of Prophylactic Cranial Irradiation and Consolidative Thoracic Radiation Therapy for Extensive Stage Small-Cell Lung Cancer in the Transition to the Chemo-Immunotherapy Era: A Single Institution Series.
    Gross AJ; Sheikh S; Kharouta M; Chaung K; Choi S; Margevicius S; Fu P; Machtay M; Bruno DS; Dowlati A; Biswas T
    Clin Lung Cancer; 2023 Dec; 24(8):696-705. PubMed ID: 37993218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach.
    Zhao J; He Y; Yang X; Tian P; Zeng L; Huang K; Zhao J; Zhou J; Zhu Y; Wang Q; Chen M; Li W; Gao Y; Zhang Y; Xia Y
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Thoracic radiation therapy improves the prognosis for patients with extensive stage small-cell lung cancer].
    Zhu H; Zhou ZM; Feng QF; Ou GF; Liang J; Zhang XR; Zhang HX; Chen DF; Xiao ZF; Wang LH
    Zhonghua Zhong Liu Za Zhi; 2011 Feb; 33(2):142-6. PubMed ID: 21575486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety comparison of PD-1 inhibitors
    Yang G; Sun H; Sun N; Huang W; Wang Z; Zhang H; Liu C
    J Thorac Dis; 2022 Dec; 14(12):4925-4937. PubMed ID: 36647464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy.
    Tian Y; Ma J; Jing X; Zhai X; Li Y; Guo Z; Yu J; Zhu H
    Cancer Lett; 2022 Aug; 541():215719. PubMed ID: 35597478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapy.
    Giuliani ME; Atallah S; Sun A; Bezjak A; Le LW; Brade A; Cho J; Leighl NB; Shepherd FA; Hope AJ
    Clin Lung Cancer; 2011 Nov; 12(6):375-9. PubMed ID: 21729647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can consolidative thoracic radiotherapy improve outcomes in extensive-disease small cell lung cancer after chemotherapy with complete/near-complete responders?
    Kirakli EK; Yilmaz H; Akcay C; Komurcuoglu B; Yilmaz U
    J Cancer Res Ther; 2020; 16(4):752-756. PubMed ID: 32930114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.
    Zhang T; Li W; Diwu D; Chen L; Chen X; Wang H
    Front Immunol; 2023; 14():1197044. PubMed ID: 37435087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
    Zeng R; Liu F; Fang C; Yang J; Luo L; Yue P; Gao B; Dong Y; Xiang Y
    Front Immunol; 2021; 12():724443. PubMed ID: 34777341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
    Liu SV; Reck M; Mansfield AS; Mok T; Scherpereel A; Reinmuth N; Garassino MC; De Castro Carpeno J; Califano R; Nishio M; Orlandi F; Alatorre-Alexander J; Leal T; Cheng Y; Lee JS; Lam S; McCleland M; Deng Y; Phan S; Horn L
    J Clin Oncol; 2021 Feb; 39(6):619-630. PubMed ID: 33439693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study.
    Choi MG; Kim YJ; Lee JC; Ji W; Oh IJ; Lee SY; Yoon SH; Lee SY; Lee JE; Kim EY; Choi CM
    Cancer Res Treat; 2024 Apr; 56(2):422-429. PubMed ID: 37871898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: A network meta-analysis.
    Yang C; Xuan T; Gong Q; Dai X; Wang C; Zhang R; Zhao W; Wang J; Yue W; Li J
    Thorac Cancer; 2024 May; 15(15):1246-1262. PubMed ID: 38623838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.